Drug Profile
Research programme: selective nicotinic acetylcholine receptor agonists - Suven Life Sciences
Alternative Names: SUVN F90101; SUVN-F91201Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Suven Life Sciences
- Class Neuroprotectants
- Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Cannabinoid receptor CB2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Metabolic disorders
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Metabolic-disorders in India
- 20 Feb 2018 Suven Life Sciences has patent protection for alpha-4-beta-2 compounds in South Korea and India
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in India